Immuneering (NASDAQ:IMRX) Earns Buy Rating from Analysts at HC Wainwright

Analysts at HC Wainwright initiated coverage on shares of Immuneering (NASDAQ:IMRX) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 218.91% from the company’s current price.

A number of other research firms have also recently weighed in on IMRX. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Finally, Cantor Fitzgerald initiated coverage on Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Immuneering currently has a consensus rating of “Buy” and a consensus target price of $18.00.

Immuneering Trading Down 0.2%

Shares of IMRX opened at $4.39 on Thursday. The firm has a market cap of $284.03 million, a P/E ratio of -3.75 and a beta of 0.43. Immuneering has a 12 month low of $2.90 and a 12 month high of $10.08. The stock’s 50 day moving average is $4.60 and its two-hundred day moving average is $4.98.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The firm had revenue of $0.36 million during the quarter. Equities research analysts forecast that Immuneering will post -1.09 EPS for the current year.

Institutional Trading of Immuneering

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Immuneering during the 1st quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering in the 4th quarter valued at about $33,000. Levin Capital Strategies L.P. purchased a new stake in shares of Immuneering in the 1st quarter valued at approximately $53,000. Focus Financial Network Inc. purchased a new stake in shares of Immuneering in the 2nd quarter valued at approximately $62,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Immuneering during the 1st quarter worth approximately $67,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.